The phase 3 EPOCH trial (NCT01483027) randomised 428 patients with liver-dominant mCRC 1:1 to Y-90 glass TARE plus chemotherapy or chemotherapy alone to compare the efficacy of these therapies in the second-line [2]. The primary analysis showed improved progression-free survival (PFS), and hepatic PFS in the combination arm compared with the chemotherapy arm. Dr William Harris (Seattle Cancer Care Alliance, WA, USA) presented the results from subgroup analyses and additional endpoints of this trial.
Subgroup analyses showed that males (HR 0.65), patients with KRAS mutations (HR 0.57), patients with a hepatic tumour burden between 10 and 25% (HR 0.43), patients with a biological agent added to their treatment regimen (HR 0.58), and patients with baseline carcinoembryonic antigen (CEA) levels ≥35 ng/mL benefitted significantly from the combination regimen compared with chemotherapy alone, with regard to PFS. In addition, all other subgroups displayed numerical trends towards a PFS benefit for the combination regimen over the standard of care arm.
Furthermore, objective response rates were higher in the combination arm (34.0%) than in the chemotherapy arm (21.1%; P=0.0019). In addition, the disease control rates numerically favoured the TARE plus chemotherapy arm over the standard of care arm (79.5% vs 72.8%; P=0.063). Also, the median duration of disease control was higher in patients treated with TARE and chemotherapy (7.2 vs 5.8 months; P=0.0009). Finally, the mean depth of response was significantly improved in the combination arm compared with the chemotherapy arm, as displayed by the mean change from baseline to nadir (-25.6% vs -13.0%; P=0.0001).
- Harris WP, et al. Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of Patient Subgroups in the EPOCH Trial. Abstract 115, ASCO GI 2022, 20–22 January.
- Mulcahy MF, et al. J Clin Oncol. 2021;39(35):3897–3907.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer Next Article
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma »
« TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer Next Article
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma »
Table of Contents: ASCO GI 2022
Featured articles
Oesophageal and Gastric Cancer
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
Anal and Colorectal Cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
Hepatobiliary Cancer
Adjuvant S-1 therapy superior to observation in resected biliary tract cancer
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma
TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
LAUNCH: TACE plus lenvatinib efficacious in advanced HCC
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC
Pancreatic Cancer
Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer
TRYbeCA-1: Eryaspase + chemotherapy does not meet primary endpoint in pancreatic cancer
Persisting disparities in pancreatic cancer care
ctDNA promising biomarker for recurrence of pancreatic cancer
Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com